拉莫三嗪——通过阻断谷氨酸释放发挥抗帕金森病活性？

Lamotrigine--antiparkinsonian activity by blockade of glutamate release?

作者信息

Zipp F, Baas H, Fischer P A

机构信息

Department of Neurology, University of Frankfurt, Frankfurt/Main, Federal Republic of Germany.

出版信息

J Neural Transm Park Dis Dement Sect. 1993;5(1):67-75. doi: 10.1007/BF02260916.

DOI:10.1007/BF02260916

PMID:8094961

Abstract

Recent experiments provide evidence that the NMDA-antagonist MK-801 has a locomotor-stimulating effect in monoamine-depleted rodents. These findings are based upon a hypothetical pathway-circuit including the basal ganglia as a model reflecting hypo- and hyperkinetic movement disorders. We have treated 5 patients suffering from Parkinson's disease with the antiepileptic drug "lamotrigine" which does not appear to be an NMDA-antagonist but acts functionally as a glutamate antagonist by inhibition of presynaptic glutamate release.

摘要

最近的实验提供了证据，表明NMDA拮抗剂MK-801对单胺耗竭的啮齿动物具有运动刺激作用。这些发现基于一个假设的通路回路，该回路以基底神经节为模型，反映运动过少和运动过多的运动障碍。我们用抗癫痫药物“拉莫三嗪”治疗了5名帕金森病患者，该药物似乎不是NMDA拮抗剂，但通过抑制突触前谷氨酸释放，在功能上作为谷氨酸拮抗剂起作用。